Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer


Bristol Myers Squibb Co BMY announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC).

  • The data showed that neoadjuvant treatment with three Opdivo (nivolumab) cycles combined with chemotherapy significantly improved event-free survival (EFS) than chemotherapy alone.
  • With a minimum follow-up of 21.0 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression, or death by 37% across randomized patients when administered before surgery. 
  • Related: FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting.
  • In patients receiving the combination, median EFS was 31.6 months, compared to 20.8 months for patients treated with chemotherapy alone.
  • However, the new data unveiled, Opdivo's secondary overall survival measure, did not reach statistical significance.
  • According to Bristol Myers, 83% of patients taking Opdivo combined with chemotherapy were alive after two years, compared to 71% on chemo alone. 
  • Bristol Myers noted overall survival (OS) would continue to be followed for additional analyses.
  • Price Action: BMY shares are down 1.30% at $76.76 during the market session on the last check Monday.
  • Editor's Note: The post has been updated to clarify that overall survival data are immature and analyses are ongoing.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!